We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

BerGenBio

Q218 results highlight progress made in the period

Lighthouse | 23 August 2018

Nexstim

The defining inflection point expected within three weeks

Update | 17 August 2018

Nexstim

First NBT system delivered in US for Major Depression indication

Lighthouse | 16 August 2018

Bonesupport

Transitioning with growing confidence

Update | 30 July 2018

Tissue Regenix

Creating the right conditions for future growth

Initiation | 23 July 2018

MaxCyte

Good CARMA: IND milestone achieved

Update | 16 July 2018

Nexstim

Entering the next stimulating phase

Initiation | 02 July 2018

BerGenBio

Biomarkers point the way ahead

Update | 27 June 2018

BerGenBio

Phase II NSCLC combination study to advance into second stage

Lighthouse | 26 June 2018

Bonesupport

Growing US CERAMENT BVF in-market sales

Lighthouse | 21 June 2018
1 2 3 4 5 6 7 8 9 10 11 12 13 14
136 results found.